Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide

In prespecified final analysis of RCT (n=1509), percentage of patients alive at 3 years was significantly higher among those on darolutamide, a structurally distinct androgen-receptor inhibitor vs. placebo (83% vs. 77%; HR for death, 0.69; 95% CI, 0.53 to 0.88; p=0.003).


New England Journal of Medicine